Wednesday, October 15, 2025
As procedural changes at the PTAB are limiting opportunities for relief, eyes are now on the ITC. The Federal Circuit’s recent decision in Lashify has now made the ITC an interesting potential forum for pharma-biotech patent disputes. In this session, experienced litigators will walk us through Lashify and circumstances in which the ITC may be a good option.
- Examining how the Federal Circuit’s decision in Lashify may be a game changer for life sciences companies to use the ITC as a means of patent enforcement
- Understanding how the new interpretation of the domestic industry requirement can open the door for more bio-pharma patent disputes in this forum - Highlighting the benefits and downsides of filing disputes at the ITC
- Examining the tension between the PTAB and the ITC
Event Details
Wednesday, October 15, 2025
3 Times Square
3 Times Square, Level 16, New York, New York 10036
Speakers
Disclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
